Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601

Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma

(2015) Tadeusz Robak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mantle cell lymphoma epidemiology: a population-based study in France

(2014) Christophe Leux et al.   ANNALS OF HEMATOLOGY

Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)

(2014) J. E. Chang et al.   BLOOD

Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study

(2014) A. Abrahamsson et al.   BLOOD

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

(2014) I. W. Flinn et al.   BLOOD

SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma - a Nordic Lymphoma Group study

(2014) Lena Nordström et al.   BRITISH JOURNAL OF HAEMATOLOGY

Proteasome function is required for platelet production

(2014) Dallas S. Shi et al.   JOURNAL OF CLINICAL INVESTIGATION

Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in Randomized Trials of the European Mantle-Cell Lymphoma Network

(2014) Eva Hoster et al.   JOURNAL OF CLINICAL ONCOLOGY

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

(2013) Mathias J Rummel et al.   LANCET

An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA

(2013) Briseis Aschebrook-Kilfoy et al.   LEUKEMIA & LYMPHOMA

Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma

(2012) L. Nygren et al.   BLOOD

CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte

(2012) R. Delarue et al.   BLOOD

Treatment of Older Patients with Mantle-Cell Lymphoma

(2012) H.C. Kluin-Nelemans et al.   NEW ENGLAND JOURNAL OF MEDICINE

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

(2011) J. W. Friedberg et al.   BLOOD

Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma

(2010) Richard R. Furman et al.   CANCER

Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting

(2010) S. A. M. van de Schans et al.   HAEMATOLOGICA

Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial

(2010) André Goy et al.   LEUKEMIA & LYMPHOMA

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

(2009) John Gerecitano et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

(2008) A. Goy et al.   ANNALS OF ONCOLOGY

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

(2008) C. H. Geisler et al.   BLOOD

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

(2007) E. Hoster et al.   BLOOD